Showing results (111-120 of 218) with videos related to

Sort By:
Pageof 22
Journal of the Neurological Sciences|August 15, 2018
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapyIlya Kister, Tim Spelman, Francesco Patti, et al.
Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2025
Disease course after pregnancy in women with progressive multiple sclerosis symptomsJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 19, 2024
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase RegistryAlessio Signori, Marta Ponzano, Tomas Kalincik, et al.
Neurology and Therapy|August 3, 2024
Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical PracticeBassem Yamout, Raed Alroughani, Jihad Inshasi, et al.
The Lancet. Child & Adolescent Health|March 28, 2024
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registriesSifat Sharmin, Izanne Roos, Charles B Malpas, et al.
The Lancet. Neurology|February 21, 2026
Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGADDalia L Rotstein, Raed Alroughani, Georgina Arrambide, et al.
Neurology|March 11, 2014
Fingolimod after natalizumab and the risk of short-term relapseVilija G Jokubaitis, Vivien Li, Tomas Kalincik, et al.
Neurology|March 6, 2024
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based StudyTim Spelman, Gabrielle Simoneau, Robert Hyde, et al.
Pageof 22